Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate
Study Details
Study Description
Brief Summary
The purpose of the study is to assess the effectiveness of the HALT COVID Ambassador educational outreach program on increasing likelihood to vaccinate against COVID-19
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Investigators will use a randomized controlled trial to test the effectiveness of HALT COVID educational outreach by HALT COVID Ambassadors. HALT COVID Ambassadors will receive training to answer common vaccine questions & address misconceptions; conduct motivational interviewing; and implement basic behavioral economics and related strategies to remove barriers to vaccination. A random sample of FQHC patients will be identified in EHR data downloads of adult patients seen in the last year and contacted by telephone to gain consent and assess eligibility. A total of 100 individuals will be enrolled into the trial and randomized to intervention (engagement with the HALT COVID Ambassador over a 1 month period via in-person or virtual sessions exploring their own questions and concerns about vaccines) or usual care (no extra engagement). Baseline, 1-month, and 2-month follow-up surveys will assess for vaccine likelihood.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention
|
Behavioral: Community health worker engagement
3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
|
| No Intervention: Usual care
|
Outcome Measures
Primary Outcome Measures
- Difference in proportion of participants "likely to vaccinate" between study arms at Month 1 [Month 1 follow-up]
Vaccine likelihood will be measured using a single question adapted from the CEAL Common Survey (i.e., "On a scale from 1 to 7, with 1 being 'not at all likely' and 7 being 'very likely', how likely are you to get a COVID-19 vaccine in the next month?"), with "likely to vaccinate" defined as a score of 5-7.
Secondary Outcome Measures
- Difference in proportion of participants "likely to vaccinate" between study arms at Month 2 [Month 2 follow-up]
Vaccine likelihood will be measured using a single question adapted from the CEAL Common Survey (i.e., "On a scale from 1 to 7, with 1 being 'not at all likely' and 7 being 'very likely', how likely are you to get a COVID-19 vaccine in the next month?"), with "likely to vaccinate" defined as a score of 5-7.
- Difference in proportion of participants who have received >=1 dose of vaccine between study arms at Month 1 [Month 1 follow-up]
Receipt of vaccination will be measured by self-report
- Difference in proportion of participants who have received >=1 dose of vaccine between study arms at Month 2 [Month 2 follow-up]
Receipt of vaccination will be measured by self-report
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Unlikely to vaccinate in next month
-
Age >=18 years
-
Self-identification as Black or African American
-
Ability to understand and speak English
-
Willingness to engage with HALT COVID Ambassador via in-person or virtual sessions exploring questions and concerns about vaccines
Exclusion Criteria:
- Unable or unwilling to give informed consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Tulane University Medical Center | New Orleans | Louisiana | United States | 70112 |
Sponsors and Collaborators
- Tulane University
- National Institutes of Health (NIH)
Investigators
- Principal Investigator: Marie Krousel-Wood, MD, MSPH, Tulane University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2020-1600
- OT2 HL158260